Solid Tumors Clinical Trial
Official title:
A Phase I Study of Doxorubicin-loaded Anti-EGFR Immunoliposomes in Patients With Advanced Solid Tumors
Background: Site-specific delivery of anti-cancer therapeutics is paramount for both
reducing nonspecific toxicities and increasing efficacy of chemotherapeutic agents. Due to
their small molecular size and nonspecific mechanisms of action, most conventional
chemotherapies result in significant toxicities that limit the effectiveness of treatment
and reduce the overall quality of life for cancer patients. Encapsulation of these toxic
agents inside lipid-based carrier systems (so-called liposomes) results in passive targeting
of the compounds to solid tumors. The preferential delivery of liposomal drugs to solid
tumors is mostly due to altered barrier-properties of tumor-associated vessels. This results
in both an improved delivery and at the same time a significantly milder toxicity profile.
Recently, the specificity of delivery was further increased by attaching monoclonal
antibodies or antibody fragments to the surface of liposomes (=immunoliposomes,
antibody-linked nanoparticles). Antibody-coated immunoliposomes attach more selectively to
antigens expressed on the target cells and they are internalized more efficiently.
Furthermore, there is evidence that drug resistance, a major challenge in cancer treatment,
may be overcome by such delivery systems. A logical and accessible target, such as EGFR, is
overexpressed on a variety of primary human cancer cells and it is involved in signaling
pathways that contribute both to tumor initiation and tumor progression. Recently, the
investigators have tested immunoliposomes against the epidermal growth factor receptor
(EGFR) in a preclinical setting. Based on the preclinical results we have initiated this
phase I clinical trial.
Study hypothesis: The investigators hypothesize that anti-EGFR-immunoliposomes selectively
deliver cytotoxic compounds to EGFR-overexpressing tumors cells. Specific delivery is
supposed to increase efficacy while reducing side-effects of the compound. The primary
objective of this phase 1 trial is the determination of the maximum tolerated dose (MTD) for
future phase 2 trials of this nanoparticle.
C225-ILS-DOX
This is a phase 1 trial of anti-EGFR-immunoliposomes, an investigative nanoparticle targeted
against EGFR-overexpressing tumor cells. The investigators have constructed anti-EGFR
immunoliposomes by using Fab' fragments of the chimeric MAb cetuximab (C225, cetuximab,
erbitux™, ImClone Systems Corp., NY, USA; Merck KGaA, Darmstadt, Germany), which were
covalently conjugated to the liposome membrane. This approach was designed to provide
maximal drug delivery to cancer cells via a receptor-targeted and internalizing drug carrier
that is stable, non-immunogenic, long-lived with extended blood and tissue residence times
and capable of delivering large payloads of diverse types of drugs.
Based on extensive preclinical studies, the investigators decided to perform a
first-in-human clinical trial in patients with EGFR-overexpressing solid tumors who have
already received all available standard treatments. The therapeutic compound tested in the
trial is C225-ILs-dox, a doxorubicin-loaded anti-EGFR-immunoliposome. Doxorubicin is one of
the most active agents in many human tumors, and a high percentage of these malignancies do
express EGFR. Therefore, the targeting of doxorubicin to EGFR-expressing tumors via the
EGFR-specific antibody C225 should enhance the specificity and efficacy of chemotherapy,
while the encapsulation of the cytotoxic drug within pegylated liposomes should at the same
time decrease its toxicity.
This is a single center, open study. The aim of the trial is the definition of the maximum
tolerated dose (MTD) for future phase 2 studies. Secondary endpoints include the overall
response rate, the time-to-progression and the assessment of the pharmakokinetic of the
compound. The trials follows a canonical 3+3 design and allows an additional recruitment of
up to 6 patients on the dose level defined as the MTD. Planned dose levels are as follows:
Level 1 = 5 mg/m2 Level 2 = 10 mg/m2 Level 3 = 20 mg/m2 Level 4 = 30 mg/m2 Level 5 = 40
mg/m2 Level 6 = 50 mg/m2 Level 7 = 60 mg/m2 Level 8 = 70 mg/m2 Level 9 = 80 mg/m2
At each dose level, 3 patients may be enrolled simultaneously. Escalation to the next higher
dose will be allowed after patient 3 of a given dose level has received at least one full
cycle of therapy if no dose limiting toxicity (DLT) occured at a given dose level. The
decision to enter a next dose level will be made by the study team after reviewing all
available toxicity data of the previous groups. A DLT is defined as any grade 4 toxicity,
any grade 3 toxicity lasting more than one week or/and febrile neutropenia grade 3 (defined
as neutrophils < 1.0 x 10e9/l and fever > 38.5 °C). Nausea, vomiting, anorexia, and alopecia
(grade 2) will be excluded as dose limiting toxicities. Similarly, adverse events that are
clearly related to the primary tumor, such as progression of disease will not be considered
as DLTs. In addition, preexisting toxicities must be taken into account when defining and
analyzing DLTs.
Patients will be treated until disease progression but for a maximum of 6 cycles. Patients
having completed the treatment phase (24 weeks) and showing complete or partial response as
well as stable disease will enter the observation phase of the study. This phase will end 12
months after the last patient has been included. At any time during treatment phase or
observation phase, patients with signs of disease progression according to RECIST criteria
for reporting results of cancer treatment or having discontinued treatment due to
unacceptable toxicity will go off study and be treated at the investigator's discretion.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |